Status:
UNKNOWN
Antibodies Response to mRNA Vaccine Against Covid-19
Lead Sponsor:
University of Roma La Sapienza
Collaborating Sponsors:
ICOT University Hospital
Conditions:
Covid-19
Eligibility:
All Genders
18-80 years
Brief Summary
Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the moment is the mRNA-based BNT162b2 and is given to Hospital employers. The investigators undertake this study t...
Detailed Description
Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the moment is the mRNA-based BNT162b2 and is given to Hospital employers. The investigators undertake this observ...
Eligibility Criteria
Inclusion
- Hospital employers vaccinated against Sars-Cov2
Exclusion
- none
Key Trial Info
Start Date :
January 28 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2022
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04733807
Start Date
January 28 2021
End Date
February 1 2022
Last Update
May 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICOT-Sapienza University Hospital
Latina, LT, Italy, 04100